Madrigal Pharmaceuticals (acquired by Synta Pharmaceuticals) Company
.png)
Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including diabetes, dyslipidemia and cardiovascular disease.
Industry:
Geroscience
Headquarters:
Washington, Pennsylvania, United States
Zip:
11-50
Founded Date:
2011-01-01
Employees Number:
11-50
Acquisitions Number:
2
Investors Number:
288375018
Total Funding:
$1M to $10M
Estimated Revenue:
2013-08-13
Last Funding Date:
Post-IPO Debt
Last Funding Type:
info@madrigalpharma.com
Register and Claim Ownership